TheraP: A randomised phase II trial of <sup>177</sup>Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).
Distribution of the number of citations over years.